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Recombinant human interferon  -2A (rhIFN- -2A) has been crystallized in
complex with the recombinantly produced Fab fragment of a therapeutic mono-
clonal antibody (MEDI545; IgG1/ ) which targets several human interferon  
subtypes. This constitutes the ﬁrst reported crystals of a human type I interferon
bound to an antibody. The orthorhombic crystals belonged to either space group
I222 or I212121, with unit-cell parameters a = 134.82, b = 153.26, c = 163.49 A ˚ .
The diffraction of the crystals extended to 3.0 A ˚ resolution. The asymmetric unit
contained two Fab–rhIFN- -2A complexes. This corresponded to a crystal
volume per protein weight (VM)o f3 . 0 2A ˚ 3 Da
 1 and a solvent content of 59.3%.
The corresponding three-dimensional structure is expected to shed light on the
mechanism of action of MEDI545 and the molecular basis of its speciﬁcity.
1. Introduction
Type I interferons (IFNs) are a family of cytokines that are expressed
from over 15 functional genes and include IFN- , IFN- , IFN- ,
IFN- , IFN-", IFN-  and IFN-!. Interferons, in particular IFN-  and
IFN- , have historically been characterized in terms of their role in
modulating the responses of mammalian hosts to infections (Isaacs &
Lindenmann, 1957; Gresser et al., 1976; Alshariﬁ et al., 2008). How-
ever, it is becoming increasingly clear that they also play a key role in
immune regulation and autoimmune diseases (Baccala et al., 2005;
Theoﬁlopoulos et al., 2005). The IFN-  family alone comprises at
least 13 different subtypes (Foster & Finter, 1998) and is thought to
play a role in systemic lupus erythematosus (SLE), type I diabetes,
Sjo ¨gren’s syndrome and thyroid diseases (Selmi et al., 2006). This
attractive targeting potential led to the development by MedImmune
of MEDI545, a fully human monoclonal antibody which exhibits
binding to multiple IFN-  subtypes. MEDI545 is currently under-
going several human clinical trials for various indications such as
lupus, chronic plaque psoriasis, dermatomyositis and poliomyelitis
(http://www.clinicaltrials.gov).
In an effort to better understand the molecular basis of the
recognition of IFN-  molecules by MEDI545, we set out to solve the
X-ray crystal structure of the complex between the Fab fragment of
this antibody and human IFN- -2A. Three type I human interferon
structures have previously been determined using either X-ray
crystallography or NMR. These correspond to human IFN- -2a,
IFN- -2b and IFN-  (Radhakrishnan et al., 1996; Karpusas et al.,
1997; Klaus et al., 1997). Here, the ﬁrst reported diffracting crystals of
a human type I interferon bound to an antibody are described and
characterized.
2. Materials and methods
2.1. Expression and purification of MEDI545 Fab and rhIFN-a-2a
The heavy and light chains of the Fab fragment of MEDI545
(IgG1/ ) were cloned into a mammalian expression vector. More
precisely, each chain was placed under the control of its own human
cytomegalovirus major immediate early (hCMVie) promoter and
enhancer (described in Boshart et al., 1985). Each of those two genesalso incorporated an SV40 poly-A sequence to allow proper pro-
cessing of its 30 end. In this system, a human  1 chain truncated at
position Lys235 (according to the Kabat numbering convention;
Kabat et al., 1991) is secreted along with a human   chain (Oganesyan
et al., 2008). The construct was then transiently transfected into
human embryonic kidney (HEK) 293 cells using Lipofectamine
(Invitrogen, Carlsbad, California, USA) and standard protocols.
MEDI545 Fab was typically harvested 72, 144 and 216 h post-trans-
fection. Conditioned media containing the soluble Fab fragment were
then dialyzed against 50 mM sodium acetate pH 5.2, 20 mM NaCl and
puriﬁed using a HiTrap HP SP column in a NaCl gradient according
to the manufacturer’s instructions (GE Healthcare, Piscataway, New
Jersey, USA). Puriﬁed MEDI545 Fab, typically >95% homogeneous
as judged by SDS–PAGE, was then concentrated to approximately
30 mg ml
 1.
High-qualitynearly 100%homogeneous Escherichiacoli-expressed
recombinant human interferon  -2A (rhIFN- -2A) was purchased
directly from Potomac Afﬁnity Proteins LLC (Rockville, Maryland,
USA). The cytokine’s mature sequence corresponded to residues 24–
188 of entry No. P01563 of the Swiss-Prot protein database (http://
www.expasy.org) and included two extra threonine and serine resi-
dues on its N-terminal end. MEDI545 Fab and rhIFN- -2A were
mixed in a 1.2:1 molar ratio. The resulting mixture was then adjusted
to approximately 10 mg ml
 1. The complex was further puriﬁed by
size-exclusion chromatography using a Superdex S200 column (GE
Healthcare) equilibrated with 20 mM sodium acetate pH 5.2, 20 mM
NaCl at a ﬂow rate of 0.5 ml min
 1. After separation from excess
MEDI545 Fab, the complex was concentrated to 6.5 mg ml
 1 using an
Amicon YM-30 concentrator (Millipore, Billerica, Massachusetts,
USA).
2.2. Crystallization screening and optimization
Sitting-drop crystallization experiments were initially set up in
96-well plates with conical ﬂat-bottomed drop compartments
(Corning 3785; VWR, West Chester, Pennsylvania, USA) using a
Phoenix crystallization robot (Art Robbins, Sunnyvale, California,
USA). Favorable conditions were initially identiﬁed using the
following commercially available crystallization screens: Crystal
Screen HT, Index Screen, SaltRx (Hampton Research, Aliso Viejo,
California, USA) and ProPlex (Molecular Dimensions, Apopka,
Florida, USA). For further optimization purposes, a commercially
available kit was used (Additive Screen HT; Hampton Research).
More particularly, in screening mode the reservoirs and drop
compartments of the 96-well plates were ﬁlled with 99 and 0.3 ml,
respectively, of the various screen solutions using the Phoenix robot.
0.3 ml of the MEDI545Fab–rhIFN- -2Acomplexataconcentrationof
6.5 mg ml
 1 was then added to the drop compartment. In optimiza-
tion mode, the reservoirs were ﬁrst ﬁlled with 80 ml screen solution.
20 ml of the various additives were then added and the reservoirs
were subjected to ﬁve cycles of mixing by aspiration/dispensing. 0.3 ml
of each reservoir solution was then mixed with 0.3 ml of the MEDI545
Fab–rhIFN- -2A complex at a concentration of 6.5 mg ml
 1 in the
drop compartment. Diffraction-quality crystals were grown in
hanging drops once optimal conditions had been identiﬁed (see x3).
2.3. X-ray diffraction data collection and processing
Diffraction data were collected from a single crystal at the Center
for Advanced Research in Biotechnology (CARB, University of
Maryland Biotechnology Institute, Rockville, Maryland, USA) using
a MicroMax-007 rotating-anode generator ﬁtted with an R-AXIS
IV
++ imaging plate (Rigaku/MSC, The Woodlands, Texas, USA). The
crystal was harvested using a litho-loop and ﬂash-cooled in a liquid-
nitrogen stream using an X-stream 2000 cryogenic cooler (Rigaku/
MSC). Prior to this step, cryoprotection was achieved by soaking the
crystal in 200 mM NaI, 8 mM NiCl2.6H2O, 80 mM Tris–HCl pH 8.5,
16%(w/v) polyethylene glycol monomethyl ether 2000, 20% glycerol.
240 consecutive images were collected using an oscillation range of
0.5 , a crystal-to-detector distance of 250 mm and an exposure time of
600 s. The diffraction images were integrated and scaled using HKL-
2000 (Otwinowski & Minor, 1997).
3. Results and discussion
Crystals of less than 10 mm in size and of tetragonal bipyramidal
shape appeared during the screening process with Crystal Screen HT
under condition H9 [0.01 M NiCl2.6H2O, 0.1 M Tris–HCl pH 8.5,
20%(w/v) polyethylene glycol monomethyl ether 2000] as seen in
Fig. 1(a). During the optimization process, crystals of similar
morphology appeared in almost all of the conditions of the Additive
Screen. However, the largest crystals were obtained when using
additives B8 (1.0 M NaI), D3 (0.1 M spermine–HCl) and D4 [0.1 M
cobalt(III) hexammine chloride]. Hanging drops were then set up
under those various conditions using 1 ml of the MEDI545 Fab–
rhIFN- -2A complex at a concentration of 3.5 mg ml
 1 in 20 mM
sodium acetate pH 5.2, 20 mM NaCl and 1 ml of the appropriate
crystallization communications
Acta Cryst. (2009). F65, 14–16 Oganesyan et al.   Interferon  -2A–Fab fragment complex 15
Figure 1
Crystals of the MEDI545 Fab–rhIFN- -2a complex. (a) Screening. The crystals shown were obtained during the initial screening phase using Crystal Screen HT (Hampton
Research) under condition H9 [0.01 M NiCl2.6H2O, 0.1 M Tris–HCl pH 8.5, 20%(w/v) polyethylene glycol monomethyl ether 2000]. (b) Optimization. The crystals shown
grew to dimensions of up to 0.1   0.1   0.2 mm in hanging drops when 1 ml reservoir solution [200 mM NaI, 8 mM NiCl2.6H2O, 80 mM Tris–HCl pH 8.5, 16%(w/v)
polyethylene glycol monomethyl ether 2000] was mixed with 1 mlo fa3 . 5m gm l
 1 MEDI545 Fab–rhIFN- -2A solution in 20 mM sodium acetate pH 5.2, 20 mM NaCl.reservoir solutions. Diffraction-quality orthorhombic crystals grew in
about 15 d when 200 mM NaI, 8 mM NiCl2.6H2O, 80 mM Tris–HCl
pH 8.5, 16%(w/v) polyethylene glycol monomethyl ether 2000 was
used as the reservoir solution. They reached dimensions of up to
0.1   0.1   0.2 mm, as seen in Fig. 1(b).
SDS–PAGE analysis of these crystals conﬁrmed that they indeed
contained the expected complex formed by MEDI545 Fab and the
recombinant human interferon  -2A (see Fig. 2). Incidentally, the
SDS–PAGE proﬁle of MEDI545 Fab also demonstrated the presence
of the expected interchain disulﬁde bond between C /Cys214 and
CH1/Cys233 (Kabat numbering; Kabat et al., 1991) owing to its
differential migration pattern under reducing and nonreducing con-
ditions (see Fig. 2).
The diffraction limit of the crystal was 3.0 A ˚ (see Fig. 3). The
possible space groups were determined to be either I222 or I212121,
with unit-cell parameters a = 134.82, b = 153.26, c = 163.49 A ˚ .T h e
asymmetric unit contained two MEDI545 Fab–rhIFN- -2A com-
plexes. This corresponded to a VM of 3.02 A ˚ 3 Da
 1 and a solvent
content of 59.3%. Data-collection statistics are shown in Table 1.
Structure determination using molecular replacement is currently
under way.
We are grateful to Potomac Afﬁnity Proteins LLC (Rockville,
Maryland, USA) for help in providing rhIFN- -2A. MEDI545 is a
fully human IgG1 anti-interferon   antibody that was generated by
Medarex in mice transgenic for human immunoglobulin genes.
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Table 1
X-ray diffraction data-collection statistics.
Values in parentheses are for the highest resolution shell.
Wavelength (A ˚ ) 1.54
Resolution (A ˚ ) 23.0–3.0 (3.11–3.0)
Space group I222 or I212121
Unit-cell parameters (A ˚ ) a = 134.82, b = 153.26, c = 163.49
Total reﬂections 156727
Unique reﬂections 34084
Average redundancy 4.6 (4.3)
Completeness (%) 99.8 (99.4)
Rmerge 0.119 (0.423)
Mean I/ (I) 7.8 (2.7)
Figure 2
SDS–PAGE proﬁle of adissolved crystal of the MEDI545 Fab–rhIFN- -2a complex
under reducing and nonreducing conditions. The 4–20% gradient gel (BioRad,
Hercules, California, USA) was stained with Bio-Safe Coomassie Stain (BioRad).
It shows rhIFN- -2a migrating at around 15 and 20 kDa under nonreducing and
reducing conditions, respectively. This difference is likely to be attributable to the
presence of two internal disulﬁde bonds, the reduction of which alters the
compactness (and thus the migration) of the molecule. The same argument can be
applied to the MEDI545 Fab fragment, which migrated slightly under its expected
molecular weight of 50 kDa under nonreducing conditions. As expected, its heavy
and light chains both migrated at 25 kDa under reducing conditions.
Figure 3
Diffraction image of a MEDI545 Fab–rhIFN- -2a crystal.